Varma Mutual Pension Insurance Co Purchases New Shares in Edwards Lifesciences Corporation $EW

Varma Mutual Pension Insurance Co bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 123,458 shares of the medical research company’s stock, valued at approximately $11,168,000.

Other hedge funds have also modified their holdings of the company. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the 1st quarter worth $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. Finally, TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences during the second quarter worth $27,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EW shares. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Finally, Barclays reiterated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

EW opened at $89.89 on Monday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a fifty day simple moving average of $89.21 and a 200 day simple moving average of $84.68. The stock has a market cap of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,570 shares of company stock valued at $2,219,390 over the last 90 days. 0.31% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.